Our achievementsSeveral prestigious prizes were awarded to our researchers. We are proud of their achievements and congratulate the winners wholeheartedly. Here you can find a selection of the award highlights of 2021.
Royal decorations for Jolanda de Vries and Nicoline HoogerbruggeNicoline Hoogerbrugge and Jolanda de Vries were appointed by His Majesty as Knight in the Order of the Dutch Lion, a highly prestigious decoration. read more
Royal decorations for Jolanda de Vries and Nicoline Hoogerbrugge
Two researchers from Radboud Institute Molecular Life Sciences (RIMLS) received a phone call from Hubert Bruls, Mayor of Nijmegen, in the morning of Monday 26 April 2021. He announced that they will receive a royal decoration because of their exceptional scientific and/or social merits.
Appointed as Knight of the Order of the Netherlands Lion are:
- Nicoline Hoogerbrugge, Tumours of the digestive tract
- Jolanda de Vries, Vascular damage
Nicoline Hoogerbrugge joined the Radboudumc in 1999 after she had worked as an internist at the ErasmusMC in the field of prevention of cardiovascular diseases. At the Radboudumc she started to focus on hereditary cancer; at the time a new field of study that focused on the early detection or prevention of tumors in patients with a hereditary predisposition to develop tumors.
In 2009 Nicoline Hoogerbrugge was appointed Professor of Hereditary Cancer. Since 2010 she has been a chain owner of hereditary cancer at the Radboudumc and in 2015 she became head of the Radboudumc Expertise Center for Hereditary Cancer. Within the Radboudumc Center for Oncology she represented the interests of preventive oncology for many years as a member of the board.
Nicoline Hoogerbrugge is a passionate physician and scientist. She is committed to her patients and colleagues and to the development of her profession. Under her wings, the Family Tumors Outpatient Clinic in the Radboudumc has taken shape and awareness of a possible hereditary predisposition and its consequences for patients and their families has greatly increased.
Again and again Nicoline Hoogerbrugge develops initiatives that are copied elsewhere in the country and improve the care for people with hereditary cancer. Her efforts as (deputy) chairman of the Hereditary Bowel Cancer Guidelines Committee, for example, have led to the Netherlands being one of the first countries in which - in the case of bowel tumours that develop at a young age - standard screening is carried out for characteristics of a hereditary predisposition: a concept that was considered controversial by many at the time.
In addition, Nicoline Hoogerbrugge is also president of the European reference network genetic tumor risk syndromes (ERN GENTURIS). In this network, healthcare professionals work together with patient organizations to better recognize and treat individuals with a hereditary predisposition to cancer. Under her chairmanship, ERN GENTURIS has grown into a very active network.
Nicoline Hoogerbrugge is a medical specialist who puts her talent at the service of many and who does much to realize her ideal: preventing cancer where possible, and providing optimal treatment where necessary.
Jolanda de Vries joined Radboudumc in 1997 in the Department of Tumor Immunology at the Center for Molecular Life Sciences Nijmegen, after receiving her PhD from 1991 to 1997 from the Department of Dermatology at the University Medical Center Utrecht. She was a pioneer from the beginning in translating dendritic cell biology into potential clinical applications.
Jolanda de Vries is a leader in tumor immunology research. She is one of the few experts in the field of cellular cancer vaccines, particularly dendritic cell vaccines. One of De Vries' successes has been the preventive vaccination of healthy carriers of Lynch syndrome, people who are at high risk of developing cancer at a young age. Another important result is the conditional admission to the basic health insurance package of treatment of skin cancer with dendritic cells from the blood. This allows for a randomized phase III study to be conducted.
Jolanda de Vries was also the first to use imaging techniques to study the effect of dendritic cells after administration in patients. For example, she showed how important the route of administration of cellular vaccines is for maximum effect.
Jolanda de Vries knows how to inspire students as well as PhDs and postdocs with different backgrounds (medical, biomedical, chemical). She is very active in informing clinicians, patients and other interested parties about the results of her research. She regularly gives lectures for patients, patient organizations and healthcare professionals. In addition, she has also taught classes in elementary schools to get children from 8 to 10 years old excited about science.
Developing cellular therapy for patients requires not only biological knowledge about the cell type, but also knowledge about how to produce drugs. In particular, knowledge is needed about the development of so-called advanced therapy medicinal products (ATMPs), which includes dendritic cell therapy. Because Jolanda de Vries is one of the few who has this knowledge, her help is requested almost every week by other scientists from the Netherlands and abroad.
Within the Department of Tumor Immunology, of which she has been Department Head since 2019, Jolanda de Vries leads the research group Human Immunology: Research and Clinical development. With the help of her VIDI, Aspacia and VICI grants, she has built a successful research team, with researchers from all over the world. Jolanda has also established international exchange programs, which have led to exchanges of postdocs, PhDs and students, and resulted in several joint publications and grants.
Young Investigator Award for Alex Garanto
Alex Garanto, Metabolic disorders has been honored with the 2021 Mary Ann Liebert, Inc. publishers Young Investigator Award of the Oligonucleotide Therapeutics Society (OTS) in recognition to his contribution to the development of antisense oligonucleotide to treat inherited retinal diseases. The award will be presented on 28 September during the 2021 Annual Meeting of the OTS.
Helma Pluk winner of RIMLS Award
The RIMLS award is an annual prize for people who have contributed a lot to the RIMLS institute. Helma Pluk is the coordinator of our research master ‘Molecular Mechanisms of Disease’. Over the last 10 years, she has managed this program and the highly talented students and contributed to the heart of our institute. Last year the master program was extensively evaluated with excellent reviews. We are proud to have Helma Pluk as our colleague.
Jolanda de Vries and Ronald van Rij appointed members of the Academia EuropaeaThis European society of scientists harbors the world's top scientists. read more
Jolanda de Vries and Ronald van Rij appointed members of the Academia Europaea
Jolanda de Vries, Vascular damage and Ronald van Rij, Infectious diseases and global health, were recently appointed members of the Academia Europaea, the European society of scientists who are among the world's top scientists.
The Academia Europaea gathers over two thousand scientists from Europe across the breadth of science. Each year, the most outstanding international candidates are selected.
Hermesdorf Prizes for COVID-19 research team and Charlotte BekkerThe entire COVID-19 research team at Radboudumc, which includes Frank van de Veerdonk, Mihai Netea, Roger Brüggemann, Leo Joosten and Alexander Hoischen, received the Hermesdorf Prize. Charlotte Bekker was awarded the Hermesdorf Talent Prize. read more
Hermesdorf Prizes for COVID-19 research team and Charlotte Bekker
The entire COVID-19 research team at Radboudumc, which includes Frank van de Veerdonk, Mihai Netea, Roger Brüggemann, Leo Joosten and Alexander Hoischen, received the 2020 Hermesdorf Prize. Charlotte Bekker was awarded the Hermesdorf Talent Prize.
Each year, the Hermesdorf Prizes are presented to senior researchers of Radboud University or Radboudumc. The Hermesdorf Talent Prize goes to a scientist at the start of her/his career. The awards are named after Prof. B.H.D. Hermesdorf, Rector Magnificus of Radboud University from late 1942 to September 1945. For reasons of principle he - as the sole Dutch Rector Magnificus - refused to present students with a declaration of loyalty to the German occupying forces, which inevitably led to the university’s closure in April 1943. He refrained from compromising his principles in trying times.
In the tradition of its namesake, the award is presented to researchers who have demonstrated unusual courage, have exerted an uncommon level of effort, or have not shied away from resistance. The award consists of a certificate and a small plaque with the image of Prof. Hermesdorf.
Winner of the Hermesdorf Prize 2020
The entire COVID-19 research team at Radboud university medical center, which includes Frank van de Veerdonk, Mihai Netea, Roger Brüggemann, Leo Joosten and Alexander Hoischen.
2020 was the year of the coronavirus pandemic, with nearly 1.5 million deaths worldwide, more than 60 million infections and each society muddling through the balancing act between life as usual and full lockdowns. Scientists from Radboudumc played a prominent role in the COVID-19 research, in which the bradykinin hypothesis, the BCG study and the genetic vulnerability for SARS-CoV-2 stood out.
In an unprecedentedly hectic year, they conducted impressive research into treatment of the corona virus. When the team of infectiologists published their hypotheses about the virus in April, the Volkskrant wrote “it grabbed the attention of doctors, scientists and pharmacists all over the world”. It is also commendable that during this busy period they still make time to explain and elaborate on these findings in national and international media outlets.
Winner of the Hermesdorf Talent Prize 2020
Charlotte Bekker, affiliated with Radboudumc, for her research on how to avoid wasting unused medicines.
Many unused medicines could, after a quality check in the pharmacy, be dispensed to another patient who needs exactly that medicine. However, current legislation does not permit that. The risk that a medicine has been stored incorrectly and its quality has deteriorated over time is considered too great. Bekker has therefore devised a special method to make reissue possible.
Anti-cancer drugs are packaged in special packaging, with a seal and a temperature logger. If these drugs are excess to requirements and are returned to the pharmacy, the seal is carefully checked to ensure it is not broken, that the drug has not been used, and that the storage temperature was not too high or too low. After a thorough check in the pharmacy, the drug can be safely dispensed to another patient. An exception to the existing legislation has been requested for this.
Hans Bloemendal Medal 2021 for Laura Kiessling
Laura Kiessling is a Novartis Professor of Chemistry at the Massachusetts Institute of Technology. MIT is also the place where she started her scientific training in chemistry. She continued her education in organic chemistry doing her PhD at Yale University. After being an American Cancer Society postdoc at California Institute of Technology, she became a professor in chemistry at the University of Wisconsin-Madison in 1991 and was director of the Keck Center for Chemical Genomics. She moved back to MIT in 2017.
She has made seminal contributions to the fields of organic synthesis, polymer chemistry and molecular biology. In addition to synthesis of glycosyl donors, modified peptides and glycopolymers, she exploits these molecules to probe carbohydrate-mediated interactions in cellular recognition and signal transduction processes. Her finding that multivalent ligands can influence receptor-ligand binding and active signaling to target immune responses has opened the way to targeted immunotherapy and other treatments.
A vast list of awards and memberships illustrates the appreciation of her research contributions by the broad scientific community. On top of that, she served as the founding editor-in-chief of ACS Chemical Biology and contributed to the education of many young chemists and biochemists. Her dedication to teaching is exemplified by the position she held previously as director of the National Institutes of Health Chemistry-Biology Interface Training Program.